Parmax Pharma: No Deviation in Utilization of Issue Proceeds for Q2 FY27

Parmax Pharma Ltd has filed a statement confirming no deviation in the utilization of funds raised through a preferential issue of equity shares and warrants. The company raised ₹19,28,19,682 on August 28, 2026. For the quarter ended September 30, 2026, the utilization of these proceeds for working capital and general corporate purposes showed no variance from the original objects. A portion of the funds was received via warrant subscription, with the balance due within 18 months.